28/02/2026
Progressive multiple sclerosis remains a major clinical challenge, particularly in SPMS and PPMS forms where disability gradually accumulates despite standard immunomodulatory treatment.
BioCells Medical is conducting an officially registered interventional study (ClinicalTrials.gov ID: NCT07146087) evaluating intravenous administration of allogeneic MSC-derived exosomes within a structured clinical framework.
The protocol assesses neurological function, disability progression markers, safety parameters and inflammatory biomarkers under physician-guided monitoring.
This research contributes structured clinical data to the ongoing scientific discussion in regenerative neurology and translational medicine.
📞 Book your individual consultation
📲 +48 453 057 307
🌐 www.biocellsmedical.com